CAPTRUST Financial Advisors
HRTX icon

CAPTRUST Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.8K Buy
47,281
+5,691
+14% +$6.59K ﹤0.01% 2923
2025
Q4 		$54.1K Sell
41,590
-7,366
-15% -$9.1K ﹤0.01% 2675
2025
Q3 		$61.7K Buy
48,956
+1,335
+3% +$2.12K ﹤0.01% 2547
2025
Q2 		$98.6K Buy
+47,621
New +$97.2K ﹤0.01% 2374
2024
Q1 		– Sell
-51,102
Closed -$86.9K – 2381
2023
Q4 		$86.9K Buy
51,102
+33,390
+189% +$36.8K ﹤0.01% 2542
2023
Q3 		$18.2K Sell
17,712
-6,198
-26% -$8.82K ﹤0.01% 2524
2023
Q2 		$27.7K Sell
23,910
-1,642
-6% -$2.93K ﹤0.01% 2452
2023
Q1 		$38.6K Buy
+25,552
New +$64K ﹤0.01% 2226
2022
Q4 		– Sell
-21,198
Closed -$89K – 2118
2022
Q3 		$89K Buy
21,198
+20,631
+3,639% +$80.7K ﹤0.01% 1947
2022
Q2 		$2K Sell
567
-518
-48% -$2.08K ﹤0.01% 4466
2022
Q1 		$6K Buy
1,085
+564
+108% +$4.13K ﹤0.01% 4065
2021
Q4 		$5K Sell
521
-370
-42% -$3.78K ﹤0.01% 4068
2021
Q3 		$10K Sell
891
-103
-10% -$1.25K ﹤0.01% 3605
2021
Q2 		$15K Buy
994
+504
+103% +$8.02K ﹤0.01% 3305
2021
Q1 		$8K Buy
490
+390
+390% +$6.95K ﹤0.01% 3540
2020
Q4 		$2K Hold
100
– – ﹤0.01% 3117
2020
Q3 		$2K Sell
100
-100
-50% -$1.56K ﹤0.01% 2766
2020
Q2 		$3K Buy
+200
New +$3.29K ﹤0.01% 2511
2019
Q4 		– Sell
-1,396
Closed -$26K – 1358
2019
Q3 		$26K Buy
1,396
+1,196
+598% +$22K ﹤0.01% 1223
2019
Q2 		$4K Hold
200
– – ﹤0.01% 1694
2019
Q1 		$5K Hold
200
– – ﹤0.01% 1526
2018
Q4 		$5K Hold
200
– – ﹤0.01% 1327
2018
Q3 		$6K Buy
+200
New +$7.45K ﹤0.01% 1330

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

CAPTRUST Financial Advisors's HRTX Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Heron Therapeutics (HRTX) stake by 14% in Q1 2026, buying an estimated $6.59K and bringing the position to 47,281 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

CAPTRUST Financial Advisors first reported a position in HRTX in Q3 2018 and has held it in 23 quarters since. The position peaked at $98.6K in Q2 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • CAPTRUST Financial Advisors held 47,281 shares of Heron Therapeutics worth $37.8K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 5,691 Heron Therapeutics shares in Q1 2026, an estimated $6.59K.
  • Heron Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2923 holding.
  • CAPTRUST Financial Advisors first reported a position in Heron Therapeutics in Q3 2018 and has held it in 23 quarters since.
  • CAPTRUST Financial Advisors's Heron Therapeutics position peaked at $98.6K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.